A detailed history of Cresset Asset Management, LLC transactions in Castle Biosciences Inc stock. As of the latest transaction made, Cresset Asset Management, LLC holds 12,405 shares of CSTL stock, worth $319,428. This represents 0.0% of its overall portfolio holdings.

Number of Shares
12,405
Previous 14,730 15.78%
Holding current value
$319,428
Previous $420,000 21.43%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 14, 2025

SELL
$26.52 - $34.67 $61,659 - $80,607
-2,325 Reduced 15.78%
12,405 $330,000
Q3 2024

Nov 14, 2024

SELL
$17.4 - $31.47 $69,252 - $125,250
-3,980 Reduced 21.27%
14,730 $420,000
Q2 2024

Aug 14, 2024

BUY
$18.84 - $24.94 $352,496 - $466,627
18,710 New
18,710 $407,000
Q2 2021

Aug 10, 2021

SELL
$50.07 - $76.78 $202,633 - $310,728
-4,047 Closed
0 $0
Q1 2021

May 12, 2021

BUY
$58.92 - $97.33 $238,449 - $393,894
4,047 New
4,047 $277,000

Others Institutions Holding CSTL

About CASTLE BIOSCIENCES INC


  • Ticker CSTL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 26,297,000
  • Market Cap $677M
  • Description
  • Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company als...
More about CSTL
Track This Portfolio

Track Cresset Asset Management, LLC Portfolio

Follow Cresset Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cresset Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cresset Asset Management, LLC with notifications on news.